These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34358459)

  • 21. Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer.
    Wang Y; Zuo M; Jin H; Lai M; Luo J; Cheng Z
    J Recept Signal Transduct Res; 2021 Jun; 41(3):304-311. PubMed ID: 32814472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA mutations in pancreatic cancer and progress in their targeting.
    Alkassis S; Yazdanpanah O; Philip PA
    Expert Opin Ther Targets; 2021 Jul; 25(7):547-557. PubMed ID: 34289788
    [No Abstract]   [Full Text] [Related]  

  • 23. A review on mechanisms of resistance to PARP inhibitors.
    Desai C; Pathak A; Limaye S; Maniar V; Joshi A
    Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the nucleotide salvage factor DNPH1 sensitizes
    Fugger K; Bajrami I; Silva Dos Santos M; Young SJ; Kunzelmann S; Kelly G; Hewitt G; Patel H; Goldstone R; Carell T; Boulton SJ; MacRae J; Taylor IA; West SC
    Science; 2021 Apr; 372(6538):156-165. PubMed ID: 33833118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
    Keung MYT; Wu Y; Vadgama JV
    J Clin Med; 2019 Mar; 8(4):. PubMed ID: 30934991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors.
    Incorvaia L; Passiglia F; Rizzo S; Galvano A; Listì A; Barraco N; Maragliano R; Calò V; Natoli C; Ciaccio M; Bazan V; Russo A
    Oncotarget; 2017 Apr; 8(14):23891-23904. PubMed ID: 28055979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP Inhibitors in Epithelial Ovarian Cancer.
    Taylor KN; Eskander RN
    Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on the safety of olaparib for treating ovarian cancer.
    Cottrell K; Clark CL; Penson RT
    Expert Opin Drug Saf; 2022 Apr; 21(4):447-451. PubMed ID: 35212587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
    Boussios S; Karihtala P; Moschetta M; Karathanasi A; Sadauskaite A; Rassy E; Pavlidis N
    Diagnostics (Basel); 2019 Aug; 9(3):. PubMed ID: 31374917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Niraparib in ovarian cancer: results to date and clinical potential.
    Caruso D; Papa A; Tomao S; Vici P; Panici PB; Tomao F
    Ther Adv Med Oncol; 2017 Sep; 9(9):579-588. PubMed ID: 29081841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.
    Murata S; Zhang C; Finch N; Zhang K; Campo L; Breuer EK
    Biomed Res Int; 2016; 2016():2346585. PubMed ID: 27642590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
    Sullivan-Reed K; Bolton-Gillespie E; Dasgupta Y; Langer S; Siciliano M; Nieborowska-Skorska M; Hanamshet K; Belyaeva EA; Bernhardy AJ; Lee J; Moore M; Zhao H; Valent P; Matlawska-Wasowska K; Müschen M; Bhatia S; Bhatia R; Johnson N; Wasik MA; Mazin AV; Skorski T
    Cell Rep; 2018 Jun; 23(11):3127-3136. PubMed ID: 29898385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
    Okuma HS; Yonemori K
    Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
    Jiang X; Li W; Li X; Bai H; Zhang Z
    Cancer Manag Res; 2019; 11():4371-4390. PubMed ID: 31191001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics.
    Murthy P; Muggia F
    Ecancermedicalscience; 2019; 13():904. PubMed ID: 30915162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session.
    Patel R; Fein D; Ramirez CB; Do K; Saif MW
    Pancreas (Fairfax); 2019; 3(1):e5-e8. PubMed ID: 32030362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
    Audeh MW
    Pharmgenomics Pers Med; 2014; 7():307-16. PubMed ID: 25342917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.
    Bortlíková L; Müller P; Vojtěšek B; Rak V; Svoboda M
    Klin Onkol; 2019; 32(Supplementum 3):19-24. PubMed ID: 31627702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.
    Lord CJ; McDonald S; Swift S; Turner NC; Ashworth A
    DNA Repair (Amst); 2008 Dec; 7(12):2010-9. PubMed ID: 18832051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
    George A; Kaye S; Banerjee S
    Nat Rev Clin Oncol; 2017 May; 14(5):284-296. PubMed ID: 27958297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.